Skip to content
  • Home
    • About Us
    • Committee
  • Abstract Submission
  • Registration
  • Programme
  • Resources
    • Blog
    • Past Summit Video
  • Sponsors
  • Venue
  • Travel Grant
  • Contact Us

Programme

  1. Home
  2. Programme
Programmeadmin2026-04-13T17:21:56+08:00
  • Main Summit

  • Speakers

  • Pre Summit Workshop

  • Post Summit Workshop

  • Main Summit

DAY 1, 15 June 2026

TIME PROGRAMME SPEAKERS
0800 – 0900 Registration
0900 – 0915 Welcome Address Ooi Eng Eong
Co-organiser, 9th ADS
0915 – 0945 Keynote Lecture Nelson Michael
WRAIR, USA
0945 – 1055 Symposium 1:
Evolving Epidemiology and Burden of Dengue (I)
Henrik Salje
Cambridge University

Borame Dickens
SSHSPH, Singapore

Tahmina Shirin
IEDCR, Bangladesh

Short talks from abstracts

1055 – 1115 Tea Break & Poster Session
1115 – 1230 Industry Symposium A (Takeda)

From Vaccine To Vaccination – Solutions For Dengue Prevention

1230 – 1330 Lunch
1330 – 1430 Symposium 2:
Evolving Epidemiology of Dengue (II)
Wee Liang En
SGH, Singapore

Jing Shen
Takeda

Martin Hibberd
LSHTM, UK

1430 – 1540 Symposium 3:
Dengue Virology and Genetics
Chantal Vogels
Yale University

Nuno Faria
Imperial College, London

Short talks from abstracts

1540 – 1600 Tea Break & Poster Session
1510 – 1600 Symposium 4:
Dengue Virus-host Interaction
Laura Martin-Sancho
Imperial College, London

Julien Pompon
IRD, France

Short talks from abstracts

1600 – 1710 Symposium 5:
Dengue Antivirals and Therapeutics
Andre Siqueira
DNDi

WHO Dengue TPP Panel discussion
Xin Hui Chan

1800 – 1900 World Dengue Day : One World Against Dengue

A dynamic 60-minute hybrid session highlighting international cooperation in dengue prevention and control, featuring brief in-person and virtual contributions from global leaders to raise awareness and foster collaboration, concluding with a symbolic group photo.

Zulkifli Ismail
ADVA

Marianne Comparet
ISNTD

Close of Day 1

DAY 2, 16 June 2026

TIME PROGRAMME SPEAKERS
0820 – 0830 Welcome Back
0830 – 0945 Symposium 6:
Dengue Pathogenesis and Immunity (I)
Adam Waickman
SUNY Upstate

Laura Rivino
Liverpool School of Tropical Medicine

Ponpan Matangkasombut
Mahidol University

Sujan Shresta
LJI, USA

0945 – 1055 Symposium 7:
Challenges in Clinical Management + Emerging Issues (I)
Giri Rajahram
QEII Hospital, Malaysia

Neelika Malavige
Sri Jayewardenepura University, Sri Lanka

Nguyen Lam Vuong
OUCRU, Vietnam

Short talks from abstracts

1055 – 1115 Tea Break& Poster Session
1115 – 1230 ADVA Educational Symposium: Innovations for Dengue and Arboviruses
1230 – 1330 Lunch
1330 – 1440 Symposium 8:
Dengue Pathogenesis and Immunity (II)
Leah Katzelnick
NIH, USA

Diana Hansen
Monash University

Sylvie Alonso
NUS, Singapore

Short talks from abstracts

1440 – 1545 Symposium 9:
Challenges in Clinical Management & Emerging Issues (II)
Chanh Ho Quang
OUCRU, Vietnam

Sophie Yacoub
Oxford University

Short talks from abstracts

1545 – 1600 Industry Talk
(Proimmune)
Chua WenZhe
1600 – 1630 World Mosquito Program
1630 – 1800 Tea Break & Poster Session
Close of Day 2

DAY 3, 17 June 2026

TIME PROGRAMME SPEAKERS
0820 – 0830 Welcome Back
0830 – 1000 ADVA-JA Dengue Slayers Challenge
1000 – 1020 Tea Break & Poster Session
1020 – 1135 Symposium 10:
Dengue Vaccines – Updates in Development
Stephen Thomas
SUNY Upstate

Shibadas Biswal
Takeda

Motoharu Abe
KM Biologics

Soumya Chatterjee
MSD

1135 – 1250 Industry Symposium
1250 – 1350 Lunch
1350 – 1505 Symposium 11:
Vector Control and Entomology
Milly Choy
NEA, Singapore

Eggi Arguni
Universitas Gadjah Mada, Indonesia

Nurulhusna Ab Hamid
MOH, Malaysia

Lim Jue Tao
NTU, Singapore

1505 – 1620 Symposium 12:
Dengue Control- RWE
Derek Cummings
JHU

Julio Croda
Universidade Federal de Mato Grosso do Sul, Brazil

Hannah Clapham
SSHSPH, Singapore

Albert Ko
Yale University

1620 – 1640 Tea Break & Poster Session
1640 – 1740 Symposium 13:
Innovative Solutions for Dengue
– Urban Planning
– Community-based care
– Innovative Financing
Panel Discussion:
Tikki Pangestu
YLL School of Medicine, NUS

Graham Alabaster
Former Director, UN-Habitat

Michelle Tan
SGH, Singapore

Patsian Low
Asia Venture Philanthropy Association (AVPN)

1740 – 1800 Closing
  • Speakers

SPEAKER COUNTRY DESIGNATION
Nelson Michael USA Director, Center for Infectious Diseases
Research Walter Reed Army Institute of Research
Henrik Salje UK Department of Genetics,
University of Cambridge
Martin Hibberd UK Faculty of Infectious & Tropical Disease
London School of Hygiene and Tropical Medicine
Tahmina Shirin Bangladesh Director, Institute of Epidemiology, Disease Control & Research
Ian Liang En Wee Singapore Consultant
Singapore General Hospital
Jing Shen UK Director, Health Economics & Modelling, Global Vaccine Business unit
Takeda Pharmaceuticals International AG
Laura Rivino UK School of Cellular and Molecular Medicine
University of Bristol
Adam Waickman USA Department of Microbiology and Immunology
Upstate Medical University
Diana Hansen Australia Associate Director (International), Biomedicine Discovery Institute
Co-Head Infection Discovery Program Monash University
Sujan Shresta USA Center for Infectious Disease and Vaccine
Research La Jolla Institute for Immunology
Leah Katzelnick USA Viral Epidemiology and Immunity
Unit National Institutes of Health
Sylvie Alonso Singapore National University of Singapore
Chantal Vogels USA Department of Epidemiology of Microbial
Diseases Yale School of Public Health
Nuno Faria UK Department of Infectious Disease
Epidemiology Imperial College London
Sophie Yacoub UK Oxford University Clinical Research Unit
(OUCRU) Ho Chi Minh City
Laura Martin-Sancho UK Department of Infectious Disease
Imperial College London
Julien Pompon France iHAT (Inter-Host Arbovirus Transmission) Team Leader
The
Institut de recherche pour le developpement (IRD)
Nguyen Lam Vuong Vietnam Oxford University Clinical Research Unit (OUCRU)
Giri Rajahram Malaysia Head of the Department of Medicine,
Queen Elizabeth II Hospital
Neelika Malavige Sri Lanka Department of Immunology and Molecular Medicine
University of Sri Jayewardenepura
Julio Croda Brazil Universidade Federal de Mato Grosso do Sul
Hannah Clapham Singapore Saw Swee Hock School of Public Health
National University of Singapore
Derek Cummings USA Johns Hopkins Bloomberg School of Public Health
Stephen Thomas USA Director, Upstate Global Health I
nstitute SUNY Upstate Medical University
Shibadas Biswal USA Head, Clinical Science, Vaccine Business
Takeda Pharmaceuticals International AG
Motoharu Abe Japan Project Leader, KM Biologics Co Ltd
Milly Choy Singapore National Environment Agency
Eggi Arguni Indonesia Faculty of Medicine
Universitas Gadjah Mada
Nurulhusna Binti Ab Hamid Malaysia Institute for Medical Research (IMR)
Borame Dickens Singapore Saw Swee Hock School of Public Health
National University of Singapore
Ho Chanh Quang Vietnam Head of Dengue Research Group
Oxford University Clinical Research Unit (OUCRU)
Albert Ko USA Department of Epidemiology of Microbial Diseases
Yale School of Public Health
Ponpan Matangkasombut Thailand Department of Microbiology, Faculty of Science
Mahidol University
  • Pre Summit Workshop

14 June 2026

Dengue Prevention – 7 Years of TAK-003 Clinical Experience, Real World Evidence Advancement and Beyond

TIME ACTIVITY
1200 – 1300 Lunch available for participants
1300 – 1315 Welcome and Global Context Setting
1315 – 1355 Long Term Clinical Evidence for TAK-003
1355 – 1445 Real-World Evidence: Safety and Effectiveness Across Diverse Settings
1445 – 1500 Tea Break
1500 – 1555 DEN-Talk (Immunology Chapter)
1. Correlates of Protection: Why Dengue is Different
2. Dengue Infection elicits skin tissue-resident T cells
3. Innate Immune Reprogramming and Emerging Concepts
4. Dichotomy between nAb and T cells
5. TAK-003 Immunology data (all arms of immunity elicited by TAK-003)
1555 – 1650 Expert Panel Discussion and Q&A
1650 – 1700 Key Takeaways and Close
  • Post Summit Workshop

18 June 2026

Asia Wolbachia Dialogue 2026

TIME ACTIVITY
0830 – 0900 Welcome and Overview
0900 – 0910 Keynote speech
0910 – 0930 Wolbachia Overview: Policy and Implementation Status
0930 – 1000 Epidemiological evidence
Tea Break
1015 – 1050 Practical considerations for selecting approaches
1050 – 1125 Wolbachia Operational Delivery Models
1125 – 1200 Wolbachia Financing and Investment Case
Lunch
1330 – 1440 Country Journeys and Plans:
1440 – 1530 Supplier Showcase
Tea Break
1545 – 1630 Donor Panel Discussion
1630 – 1645 Closing Remarks

Copyright © 2026 Asia Dengue Voice and Action Group. All Rights Reserved.
Page load link
Go to Top